BOOK ONLINE

Please select the service you would like to book:

search-button

MSI Reproductive Choices UK comment on the reclassification of the progestogen-only pill

Press releases  •  9 July 2021  • 2 min read

Share






Copied


Media statement

London, 9th July 2021

If you are covering the reclassification of the progestogen-only pill, you may find the following statement from MSI Reproductive Choices UK helpful.

Simphiwe Sesane contraceptive nurse and faculty registered trainer at MSI Reproductive Choices said:

“The reclassification of the progestogen-only pill, which can now be sold directly by a pharmacist without a prescription, is a great step forward. It will improve access and provide anyone seeking an extremely safe method of contraception more choice over how and where they access it. All too often our teams speak to people who have become pregnant while on contraception waiting lists and these challenges have only been exacerbated by the global pandemic, so this initiative is especially welcome in that context.

“However, while this reclassification is a positive move, cost will be a barrier for some. Progestogen-only contraception will continue to be available at no cost from GPs and sexual and reproductive health services, but ultimately we would like to see it available for free through NHS community pharmacies too.”

For further information please contact:

Email: [email protected]

Telephone: +44 (0) 7769 166 516


Share






Copied

Related posts

News


9 July 2021  • 3 min read

MSI Reproductive Choices Comment on 2022 Abortion Statistics for England and Wales

The Department of Health and Social Care has released the 2022 Abortion Statistics for England and Wales.

News


9 July 2021  • 2 min read

MSI Reproductive Choices UK comment on new WHO Abortion Care Guideline

MSI Reproductive Choices UK comment on launch of new World Health Organization Abortion Care Guideline Media

News


9 July 2021  • 2 min read

Marie Stopes UK comment on contraceptive shortages

Friday 7th February 2020: If you are covering today’s press release on contraceptive and